Breast Cancer Research and Treatment (2018) 168:285 https://doi.org/10.1007/s10549-017-4590-0 LE T TER TO THE EDITOR Obesity’s impact on survival is independent of dose adjustments in neoadjuvant chemotherapy in women with breast cancer 1 2 2 Ying L. Liu · Eileen P. Connolly · Kevin Kalinsky Received: 17 November 2017 / Accepted: 22 November 2017 / Published online: 24 November 2017 © Springer Science+Business Media, LLC, part of Springer Nature 2017 To the Editor, (lumpectomy vs. mastectomy) or radiation therapy rates as compared to women with normal weight (BMI 18.5 to < 25) Dr. Altundag’s comment brings to attention an important and BSA < 2.2, p > 0.05. This suggests that obesity’s nega- question about whether part of obesity’s negative impact on tive impact on survival is independent of chemotherapeutic survival in women with breast cancer receiving adriamy- dosing. cin/taxane-based chemotherapy is due to dose reduction in the cytotoxic systemic therapy. They cite a recent study by Karatas et al. in which chemotherapy doses were capped at References a body surface area (BSA) of 2 m and were not uniformly 1. Karatas F, Erdem GU, Sahin S et al (2017) Obesity is an inde- based on a patient’s exact BSA, potentially contributing to pendent prognostic factor of decreased pathological complete obesity’s negative impact on survival . In our study , response to neoadjuvant chemotherapy in breast cancer patients. we also evaluated this concept. Of the 273 women included Breast (Edinb Scotl) 32:237–244 in our study, 10 patients had high BSA (≥ 2.2) and 14 were 2. Liu YL, Saraf A, Catanese B et al (2017) Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an morbidly obese [body mass index (BMI) ≥ 40], but none of ethnically diverse population. Breast Cancer Res Treat. https:// these women had reductions in their chemotherapy doses. doi.org/10.1007/s10549-017-4507-y In addition, there were no differences in the type of surgery This is a letter to the editor submitted in response to Dr. Kadri Altundag’s letter to the editor titled “Dose adjustment in obese breast cancer patients receiving neoadjuvant chemotherapy might have an impact on survival” which was published by this journal online on October 23rd, 2017. * Kevin Kalinsky email@example.com Memorial Sloan Kettering Cancer Center, New York, NY, USA New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA Vol.:(0123456789) 1 3
Breast Cancer Research and Treatment – Springer Journals
Published: Nov 24, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud